Dave Weisman

This is not OK. I'm out of here for a long while. Thanks for all the conversations.

@AnisheeShah Get them into a clinical trial and make the future better! neurologylive.com/view/rilipruba…

When treating #cidp, we must play the long game. -Paint a picture for the treatment plan -Make short- and long-term goals at the first visit (acutely IVIG/prednisone/Plex + long-term immunomodulation if needed) -See the patient often -Counsel that steroids will be tapered over months, not days/weeks. -support disability paperwork if needed -provide guidance for assist devices Any other practical tips? #neurotwitter #neuromuscular

@AlbertoEspay @CFPC_e @alzassociation @alzforum Sad to see Canadian docs refusing to care for their fellow citizens. They can do this because patients come to the US, but it harms those who can't. This is a serious problem for social justice within their country.

Avoid using Lecanemab (#Leqembi) or Donanemab (#Kisunla) for Alzheimer's. Important advice from the College of Family Physicians of Canada (@CFPC_e). Evidence behind their conclusions: cfpclearn.ca/tfp369/ @alzassociation @alzforum #Alzheimers

When did the Onion start reporting real news? theonion.com/wealthy-hospit… via @theonion

@larrywabrams @FTC But they did try to save the gamers!

Why has the @FTC not sued the Big 3 #PBMs to get required data to complete report? Commiss Ferguson’s statement laments the interim report is based on anecdotal comments, no real data on PBM gross profits by source, comparison of PMPY drug spend outcomes Big 3 vs small PBMs . 🤷

@justin_garson @JRBneuropsiq It should be all about patient care given by people skilled enough to order and read diagnostic tests. You get that, right?

Surely Justin can tell us how to help the person with this EEG, referred to #Psychiatry because she suffers from a state of psychotic depression, with suicidal behavior (Oh! I remember that according to Justin we should just celebrate or tell the patient to have more sex)

@NEObioMATRIX @johnarnold The worst misrepresentation was the trumped up impact of amyloid56.

@johnarnold In god we trust - everyone else must bring data (and we will independently verify them)

2006 paper on cause of Alzheimer’s is the field's 4th most cited paper ever. But the author faked the data and it was later retracted. This wasted many years & $287+ million in funding as the field chased a dead end. Scientific fraud must be criminalized. chris-said.io/2024/06/17/the…

@johnarnold While this particular amyloid oligomer data might be false, it has nothing to do with the overall amyloid hypothesis which resulted in THREE AB targeting, disease modifying approvals. Unrelated note: profiteering at Enron must be criminalized.

Kisunla: Kiss-un-la or Kes-an-la or other?

@RenegadeSynapse Wow. It is like flat earth for medicine.

@dcweisman lol fear not

I am never, ever leaving this hellsite lmao

@PrTwain @sdukehan @EWidera Pick a lane. You say we have lifestyle interventions, then say we have no strong evidence of delay. What are you doing to contribute to prevention trials? Because that’s why these definitions exist.

@dcweisman @sdukehan We know much about social conditions & lifestyle variables that elevate risk for dementia. ucl.ac.uk/psychiatry/res… Arguments against biomarker definitions of AD without strong evidence of clinically significant delay of dementia by @EWidera are compelling. escholarship.org/uc/item/8d47m4…

In new Alzheimer’s criteria, some see progress while others fear profit-driven ‘diagnostic creep’ cnn.com/2024/07/01/hea…

@PrTwain @sdukehan Then how do we get to prevention?

@sdukehan Response #2 is correct

@Jeff_Browndyke @ProfRobHoward What, weren’t British politics interesting enough?

@MaryKRe I do these trials and, sorry, you're just wrong. Lec and Don background trials are a reality. While comparison trials aren’t, so far, there are drivers into placebo RCTs, mostly under insurance. But more interest thanks to more success. The future looks bright.

@dcweisman The original post is CLEAR - it’s not talking about funding, it’s talking about potentially creating a lack of available patients for future clinical trials

Some experts worry that emphasis on anti-amyloid drugs might discourage patients from participating in trials for treatments that could be better. “For the field generally, I think this is moving sideways, and it’s slowing progress,” Dr. Greicius said. nytimes.com/2024/07/02/hea…

@MaryKRe Explain further how success will FAIL to increase funding and innovation in this field. Short term or long term.

@dcweisman Think short- vs long-term, it’s really not contradictory

@javid_lab @pjie2 @EWidera Meh. @alzassociation, please vote your typo/oversight. You don’t want to go off current label. Please correct this.

@dcweisman @pjie2 @EWidera Sure. It's a testable hypothesis. And actually being tested. Which is why it's bizarre to advocate for change in policy/guidelines before said evidence is available.

Alzheimer’s Association now saying the quiet part out loud in their grand plan to attempt to both rename asymptomatic individuals with amyloid as having Stage 1 Alzheimers disease and arguing that access to amyloid antibodies “should not be delayed at ANY stage”.

@iKhushbooVerma Peds neuro to behavioral neuro. Weird, but I love it! Congratulations. Wonderful time in the field!

Nothing compares to when your patient hugs you and says they are lucky that you are their doctor. Nothing.❤ Started my #Behavioral #Neurology fellowship at Stanford.

@SuzanneESchind1 What therapy? Speculation on the mechanism?

Great work by Matt Brier finding a lower rate of amyloid pathology in older patients with multiple sclerosis. Also, interesting case of a cognitively unimpaired MS patient on immunosuppressive therapy with normal %p-tau217, very high amyloid PET burden (centiloid 109), and negative tau PET. This is telling us something important about the biology of AD. @WashUNeurology #ENDALZ @MatthewBrier @BenzingerNeuro1 @BrianGordon81 @cyrusraji onlinelibrary.wiley.com/doi/10.1002/an…